Navigation Links
Oncolytics Biotech(R) Inc. Research Collaborators Present Glioma Reovirus Research at ASV Annual Meeting
Date:7/15/2009

CALGARY, July 15 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that a poster presentation by Dr. Jacqueline Parker et al. entitled "Anti-Tumor Activity of Reovirus is Synergistically Enhanced in Combination with Temozolomide and Low Dose Irradiation in Primary Patient Glioma Xenografts Resistant to Treatment with Either Therapy Alone" was made yesterday at the 28th American Society for Virology (ASV) Annual Meeting. The meeting is being held in Vancouver, British Columbia, from July 11-15, 2009.

"These results support the strategic direction we're taking with the REOLYSIN(R) clinical program," said Dr. Matt Coffey, Chief Operating Officer for Oncolytics. "The future program for REOLYSIN, including our pivotal program, is focused on exploiting these underlying drug synergies."

The poster covers preclinical work using reovirus in combination with low dose irradiation (IR) and temozolomide (TMZ). A panel of glioma cell lines and primary patient glioma explant cells were tested for susceptibility to reovirus, IR, TMZ, or a combination of these therapies in vitro. The combination index analyses revealed moderate to strong synergy in primary patient glioma cells treated with reovirus plus IR and TMZ in vitro. This effect was also seen in vivo in flank tumor xenografts from primary patient tumors resistant to reovirus therapy alone.

The investigators concluded that the data supports the use of reovirus in combination with standard radiation and chemotherapies for the treatment of malignant glioma in humans.

The poster will be available on the Oncolytics website at www.oncolyticsbiotech.com at a later date.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the de
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carboplatin Head and Neck Cancer Trial
2. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
3. Oncolytics Biotech(R) Inc.s Research Collaborators to Present Data on REOLYSIN(R) Clinical Trials at ASCO Conference
4. Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
5. Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results
6. Oncolytics Biotech(R) Inc. Announces Details of 2009 Annual Shareholder Meeting
7. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioFinance 2009
8. Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clinical Trial
9. Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
10. Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting
11. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015  ArroGen Group, ... its new Fingerprint Molecular Identification™ (FMID) technology Aug. ... conference in Sacramento, Calif. ... science, will enable law enforcement agents, district attorneys ... of criminal suspects. By analyzing chemical ...
(Date:8/3/2015)... WESTWOOD, Mass. , Aug. 3, 2015  Merck ... company for innovative and top-quality high-tech products in the ... together with the US-based company Nano-C, their development and ... field of organic photovoltaics (OPV). Merck KGaA, Darmstadt, ... participate in the growing OPV sector. Novel ...
(Date:8/3/2015)... 2015   Intrexon Corporation (NYSE: XON ... second quarter 2015 financial results after the market closes ... will host a conference call at 5:30 PM ET ... update. The conference call may be accessed ... asking to join the "Intrexon Corporation Call."  Participants may ...
(Date:7/31/2015)... , July 31, 2015 In today,s ... that help them drive positive health outcomes, improve ... source of patient care in their communities. At ... tradeshow and conference, AmerisourceBergen announced a new set ... Services Administration Organization and help independent pharmacies endure ...
Breaking Biology Technology:ArroGen Previews New Fingerprint Molecular Identification Technology 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 3Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 4Intrexon to Announce First Half and Second Quarter 2015 Financial Results and Host Conference Call on August 10th 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3
... VALENCIA, Calif., June 16 MannKind,Corporation (Nasdaq: MNKD ), ... announced today that it,will present at upcoming conferences., ... 23, 2008 at 11:45 AM (Eastern ... Island, Massachusetts, -- 2nd Annual Jefferies Healthcare Conference ...
... FRANCISCO, June 16 The Endocrine Society, an,international association ... for security analysts. The call,originated from ENDO 08, the ... in San Francisco. The Society has over 14,000 members ... report on the latest,advances in endocrine research and clinical ...
... 16 Celator Pharmaceuticals today,announced that John Bennett, ... the BIO Business Forum during the Biotechnology Industry,Organization ... will,provide a corporate overview and an update on ... on Wednesday, June 18,2008 at 3:30 PDT in ...
Cached Biology Technology:'Breakthroughs Ahead,' Endocrine Society Tells Security Analysts 2
(Date:7/9/2015)... 07, 2015 Research ... of the "Biometrics for Banking; Market & ... report to their offering. The adoption ... this growth and the forecast is that by ... for companies involved in delivering biometric systems to ...
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. (NASDAQ: ... diagnostics, today announced the launch of a study ... Precision Cancer Monitoring℠ (PCM) technology for predicting response ... or a combination of the novel immunotherapy agents ... a PD-1 inhibitor. The 50-patient study will be ...
(Date:7/2/2015)... June 25, 2015 ... addition of the "Natural Language Processing Market ... IVR, OCR, Pattern & Image Recognition) - Worldwide ... The key vendors occupying the market ... Corporation, Microsoft Corporation, NetBase Solutions, SAS Institute Inc., ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2
... asthma has been shown to help reduce the formation ... is implicated in the development of Alzheimer,s disease, according ... The researchers published their findings, "Pharmacologic Blockade of 5-Lipoxygenase,Improves ... in the American Journal of Pathology . ...
... The long tendrils of this woody vine, or liana, ... But kudzu may be no match for the lianas of ... studies show that lianas are overgrowing trees in every instance. ... forest ecosystems. Tropical forests contain more than half of ...
... The Pancreatic Cancer Action Network and the American Association ... and E. Scott Seeley, M.D., Ph.D., the 2011 Pancreatic ... each totaling $600,000 over five years, will be formally ... April 2-6. "Because of the poor prognoses and ...
Cached Biology News:Asthma drug could help control or treat Alzheimer's disease 2Stranglers of the tropics -- and beyond 2Stranglers of the tropics -- and beyond 3Pancreatic Cancer Action Network-AACR Pathway to Leadership Grants awarded to early-career investigators 2Pancreatic Cancer Action Network-AACR Pathway to Leadership Grants awarded to early-career investigators 3Pancreatic Cancer Action Network-AACR Pathway to Leadership Grants awarded to early-career investigators 4
... Although the mixed TAMRA isomers are predominantly ... are increasingly preferred for labeling peptides and ... HPLC purification that is often required in ... used than 6-TAMRA for labeling peptides and ...
anti-Lactate Dehydrogenase...
Mouse monoclonal [6E10] to LAP2 ( Abpromise for all tested applications). entrezGeneID: 7112 SwissProtID: P42166...
Alkali soluble casein is the recommended blot blocking reagent for use with the HisTag Monoclonal Antibody (Novagen) on Western blots....
Biology Products: